Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Valion Bio r&d expenses
Research and development expenses are spending on new products and technology.
Valion Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.70M, up 283.9% year over year. For fiscal 2025 it was $3.13M, up 138.5% from the year before. The highest annual figure on record is $3.13M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13M | +138.5% |
| FY2024 | Dec 31, 2024 | $1.31M | -20.7% |
| FY2023 | Dec 31, 2023 | $1.66M | -4.3% |
| FY2022 | Dec 31, 2022 | $1.73M | +97.0% |
| FY2021 | Dec 31, 2021 | $878.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.70M | +312.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.85M | +453.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.28M | +285.3% |
| Q3 FY2025 | Sep 30, 2025 | $858.00K | +103.3% |
| Q2 FY2025 | Jun 30, 2025 | $655.00K | +116.9% |
| Q1 FY2025 | Mar 31, 2025 | $335.00K | +30.9% |
| Q4 FY2024 | Dec 31, 2024 | $333.00K | -7.5% |
| Q3 FY2024 | Sep 30, 2024 | $422.00K | +25.2% |
| Q2 FY2024 | Jun 30, 2024 | $302.00K | -35.5% |
| Q1 FY2024 | Mar 31, 2024 | $256.00K | -47.8% |
| Q4 FY2023 | Dec 31, 2023 | $360.00K | -17.2% |
| Q3 FY2023 | Sep 30, 2023 | $337.00K | -15.5% |
| Q2 FY2023 | Jun 30, 2023 | $468.00K | -5.8% |
| Q1 FY2023 | Mar 31, 2023 | $490.00K | +22.2% |
| Q4 FY2022 | Dec 31, 2022 | $435.00K | +39.0% |
| Q3 FY2022 | Sep 30, 2022 | $399.00K | +128.0% |
| Q2 FY2022 | Jun 30, 2022 | $497.00K | +158.9% |
| Q1 FY2022 | Mar 31, 2022 | $401.00K | +102.5% |
| Q4 FY2021 | Dec 31, 2021 | $313.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $175.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $192.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $198.00K | – |
See a number that looks wrong?